Revenue Net Income P/E P/S EBIT Dividend Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE

Lantheus Holdings AAQS 2025

Lantheus Holdings AAQS

Ticker

LNTH

ISIN

US5165441032

WKN

A117UE

Revenue Net Income P/E P/S EBIT Dividend Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE

Lantheus Holdings has a current AAQS of 7.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Lantheus Holdings in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

Lantheus Holdings Aktienanalyse

What does Lantheus Holdings do?

Lantheus Holdings Inc. is an American company in the field of medical technology and radiopharmaceuticals. It was founded in 1956 under the name New England Nuclear Corporation and has since built an impressive history. Initially, under the name New England Nuclear Corporation, the company focused on the manufacture of laboratory equipment and isotope technology. However, over time, the company has specialized in the development and production of radiopharmaceuticals and diagnostic imaging procedures. Today, the company offers a wide range of products that are used worldwide by medical professionals. Lantheus' business model is designed to provide solutions to the challenges of modern medical imaging. The company faces the challenges of obtaining drug approvals, developing medical devices, providing critical knowledge, and effectively penetrating the market. The company is divided into several divisions that focus on specific areas of medical imaging. These include the divisions of radiopharmaceuticals and medical imaging. Each of these divisions offers specialized products and services tailored to the needs of medical professionals and patients. Lantheus' radiopharmaceutical division specializes in the production of radiopharmaceuticals. These are used for the diagnosis and treatment of various diseases such as cancer, heart and kidney diseases, or thyroid diseases. The company specializes in the production of isotopes such as technetium-99m and rubidium-82, which are among the most commonly used radiopharmaceuticals. Lantheus' medical imaging division offers solutions for the diagnosis and examination of various diseases. This includes specialized devices and equipment used in clinics and diagnostic centers. These include devices for cardiology, neurology, or oncology, for example. One of Lantheus' most well-known products is the diagnostic agent Definity®, which is used for imaging of heart and vascular diseases. Definity® is an ultrasound contrast agent that contains inert gas bubbles that enhance the signal of ultrasound waves in the body. The agent is used to create detailed images of the heart and other organs in the body. Like many companies in the medical technology industry, Lantheus is currently facing numerous challenges, particularly regarding the long-standing debate about the cost of healthcare and access to high-quality medical imaging. Lantheus is responding to this with smart product development, particularly in the field of radiopharmaceuticals, critical knowledge, and effective market penetration. Overall, Lantheus Holdings Inc. has earned an excellent reputation in the medical technology industry. The company has tirelessly worked to create solutions for the challenges in medical imaging while keeping an eye on the latest scientific developments. Certainly, Lantheus will continue to play an important role in the development of radiopharmaceuticals and medical imaging solutions in the future. Lantheus Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Frequently Asked Questions about Lantheus Holdings stock

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Lantheus Holdings

Our stock analysis for Lantheus Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lantheus Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.